Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Altasciences Company Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2023
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Altasciences Company Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2023
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl,Ambrisentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RVT-1201 (rodatristat ethyl) is a tryptophan hydroxylase inhibitor designed to reduce body’s peripheral production of serotonin, in preclinical study comparing rodatristat ethyl monotherapy and in combination with ambrisentan, in an animal model of PAH...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2022
Lead Product(s) : Rodatristat Ethyl,Ambrisentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Altavant Sciences | Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple-Ascending Dose in Japanese Patients Bridging Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2021
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Altavant Sciences | Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Altavant Sciences | Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Altavant Sciences | Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ELEVATE 2 will test the ability of rodatristat to reduce the peripheral production of serotonin through its unique mechanism of tryptophan hydroxylase (TPH) inhibition in order to improve PAH symptoms.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2021
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 15, 2021
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The studies demonstrated enhanced distribution of rodatristat ethyl in lung tissue consistent with levels associated with disease modification in preclinical models and also demonstrated minimal brain exposure supporting a lack of impact on brain seroton...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2020
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Altavant Sciences | PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2019
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Altavant Sciences | PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2016
Lead Product(s) : Rodatristat Ethyl,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable